A meta-analysis of 83 studies showed that Aβ42, Aβ42/40, NfL and p-tau-181could effectively discriminate AD patients from controls, but it needs to rely on the novel platforms, such as Simoa and immunomagnetic reduction (IMR)55. This evidence concerns the gene NEFL and Alzheimer disease.